Dwyer L D, Miller A C, Parks A L, Jaken S, Malkinson A M
Molecular Toxicology Program, School of Pharmacy, University of Colorado, Denver 80262.
Am J Physiol. 1994 May;266(5 Pt 1):L569-76. doi: 10.1152/ajplung.1994.266.5.L569.
A few minutes after mouse lung epithelial cell lines were treated with 12-O-tetradecanoylphorbol-13-acetate (TPA), the cells rounded up and pulled away from their neighbors. Several hours later, the cells flattened out to resume their original morphology. To begin to characterize the enzymology underlying these changes, the subcellular distribution and intracellular content of the TPA receptor, protein kinase C (PKC), and its putative endogenous regulator, the Ca(2+)-dependent protease, calpain, were investigated. Of eight PKC isozymes examined in several tumorigenic and nontumorigenic cell lines, all cells contained PKC-alpha, PKC-delta, and PKC-zeta. TPA rapidly (5 min) translocated PKC-alpha from the cytosol to the particulate fraction; PKC-alpha concentrations then decreased with continued TPA exposure. PKC-zeta levels and intracellular location were not affected. An inhibitor of PKC activity, GF 109203X, prevented the initial morphological change. The calpain II isozyme was also found in all cell lines, and its cellular content increased as a result of TPA treatment. Calpain inhibitor I did not affect the initial shape change but prevented subsequent flattening of the cells. We therefore conclude that PKC activation is required for the TPA-induced alterations in lung cell morphology and that calpain mediates the return to a flattened epithelial appearance.
用12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)处理小鼠肺上皮细胞系几分钟后,细胞变圆并与相邻细胞分离。几小时后,细胞又变平以恢复其原始形态。为了开始表征这些变化背后的酶学机制,研究了TPA受体、蛋白激酶C(PKC)及其假定的内源性调节因子——钙(2 +)依赖性蛋白酶钙蛋白酶的亚细胞分布和细胞内含量。在几种致瘤和非致瘤细胞系中检测的8种PKC同工酶中,所有细胞都含有PKC -α、PKC -δ和PKC -ζ。TPA迅速(5分钟)使PKC -α从胞质溶胶转移到颗粒部分;随着TPA持续作用,PKC -α浓度随后下降。PKC -ζ的水平和细胞内位置不受影响。PKC活性抑制剂GF 109203X可阻止最初的形态变化。在所有细胞系中也发现了钙蛋白酶II同工酶,其细胞含量因TPA处理而增加。钙蛋白酶抑制剂I不影响最初的形状变化,但可阻止细胞随后变平。因此,我们得出结论,PKC激活是TPA诱导肺细胞形态改变所必需的,并且钙蛋白酶介导细胞恢复为扁平上皮外观。